|
1
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, et al: Survival in BRAF V600-mutant advanced melanoma
treated with vemurafenib. N Engl J Med. 366:707–714. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu W, Wang Y, Zhang C, Huang B, Bai J and
Tian L: Cullin1 is up-regulated and associated with poor patients'
survival in hepatocellular carcinoma. Int J Clin Exp Pathol.
8:4001–4007. 2015.PubMed/NCBI
|
|
3
|
Wang W, Chen Y, Deng J, Zhou J, Gu X, Tang
Y, Zhang G, Tan Y, Ge Z, Huang Y, et al: Cullin1 is a novel
prognostic marker and regulates the cell proliferation and
metastasis in colorectal cancer. J Cancer Res Clin Oncol.
141:1603–1612. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fan YC, Zhu YS, Mei PJ, Sun SG, Zhang H,
Chen HF, Chen C and Miao FA: Cullin1 regulates proliferation,
migration and invasion of glioma cells. Med Oncol. 31:2272014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu M, Yang X, Zhao J, Zhang J, Zhang S,
Huang H, Liu Y and Liu J: High expression of Cullin1 indicates poor
prognosis for NSCLC patients. Pathol Res Pract. 210:397–401. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bai J, Yong HM, Chen FF, Mei PJ, Liu H, Li
C, Pan ZQ, Wu YP and Zheng JN: Cullin1 is a novel marker of poor
prognosis and a potential therapeutic target in human breast
cancer. Ann Oncol. 24:2016–2022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan
Y, Zhou J and Li G: Overexpression of Cullin1 is associated with
poor prognosis of patients with gastric cancer. Hum Pathol.
42:375–383. 2011. View Article : Google Scholar
|
|
8
|
Chen G, Cheng Y, Martinka M and Li G: Cul1
expression is increased in early stages of human melanoma. Pigment
Cell Melanoma Res. 23:572–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang G and Li G: Novel multiple markers
to distinguish melanoma from dysplastic nevi. PLoS One.
7:e450372012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen G and Li G: Increased Cul1 expression
promotes melanoma cell proliferation through regulating p27
expression. Int J Oncol. 37:1339–1344. 2010.PubMed/NCBI
|
|
11
|
Spilka R, Ernst C, Mehta AK and Haybaeck
J: Eukaryotic translation initiation factors in cancer development
and progression. Cancer Lett. 340:9–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kong J and Lasko P: Translational control
in cellular and developmental processes. Nat Rev Genet. 13:383–394.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Reilly KE, Warycha M, Davies MA, Rodrik
V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, et
al: Phosphorylated 4E-BP1 is associated with poor survival in
melanoma. Clin Cancer Res. 15:2872–2878. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiarini F, Evangelisti C, McCubrey JA and
Martelli AM: Current treatment strategies for inhibiting mTOR in
cancer. Trends Pharmacol Sci. 36:124–135. 2015. View Article : Google Scholar
|
|
15
|
Zoncu R, Efeyan A and Sabatini DM: mTOR:
From growth signal integration to cancer, diabetes and ageing. Nat
Rev Mol Cell Biol. 12:21–35. 2011. View
Article : Google Scholar
|
|
16
|
Wang Z, Zhong J, Inuzuka H, Gao D, Shaik
S, Sarkar FH and Wei W: An evolving role for DEPTOR in tumor
development and progression. Neoplasia. 14:368–375. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duan S, Skaar JR, Kuchay S, Toschi A,
Kanarek N, Ben-Neriah Y and Pagano M: mTOR generates an
auto-amplification loop by triggering the βTrCP- and CK1α-dependent
degradation of DEPTOR. Mol Cell. 44:317–324. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao D, Inuzuka H, Tan MK, Fukushima H,
Locasale JW, Liu P, Wan L, Zhai B, Chin YR, Shaik S, et al: mTOR
drives its own activation via SCF(βTrCP)-dependent degradation of
the mTOR inhibitor DEPTOR. Mol Cell. 44:290–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao Y, Xiong X and Sun Y: DEPTOR, an mTOR
inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin
ligase and regulates survival and autophagy. Mol Cell. 44:304–316.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Silvera D, Formenti SC and Schneider RJ:
Translational control in cancer. Nat Rev Cancer. 10:254–266. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dowling RJ, Topisirovic I, Alain T,
Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj
A, Liu Y, et al: mTORC1-mediated cell proliferation, but not cell
growth, controlled by the 4E-BPs. Science. 328:1172–1176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kipreos ET, Lander LE, Wing JP, He WW and
Hedgecock EM: cul-1 is required for cell cycle exit in C. elegans
and identifies a novel gene family. Cell. 85:829–839. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lai EY, Chen ZG, Zhou X, Fan XR, Wang H,
Lai PL, Su YC, Zhang BY, Bai XC and Li YF: DEPTOR expression
negatively correlates with mTORC1 activity and tumor progression in
colorectal cancer. Asian Pac J Cancer Prev. 15:4589–4594. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li H, Sun GY, Zhao Y, Thomas D, Greenson
JK, Zalupski MM, Ben-Josef E and Sun Y: DEPTOR has growth
suppression activity against pancreatic cancer cells. Oncotarget.
5:12811–12819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pópulo H, Soares P and Lopes JM: Insights
into melanoma: Targeting the mTOR pathway for therapeutics. Expert
Opin Ther Targets. 16:689–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Marone R, Erhart D, Mertz AC, Bohnacker T,
Schnell C, Cmiljanovic V, Stauffer F, Garcia-Echeverria C, Giese B,
Maira SM, et al: Targeting melanoma with dual phosphoinositide
3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res.
7:601–613. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang SX, Hewitt SM, Steinberg SM, Liewehr
DJ and Swain SM: Expression levels of eIF4E, VEGF, and cyclin D1,
and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor
tissue microarray. Oncol Rep. 17:281–287. 2007.PubMed/NCBI
|
|
28
|
Jia L and Sun Y: SCF E3 ubiquitin ligases
as anticancer targets. Curr Cancer Drug Targets. 11:347–356. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gu Q, Bowden GT, Normolle D and Sun Y:
SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent
targeting of c-Jun/AP1 and IkappaB-alpha/NF-kappaB. J Cell Biol.
178:1009–1023. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen G, Cheng Y, Zhang Z, Martinka M and
Li G: Cytoplasmic Skp2 expression is increased in human melanoma
and correlated with patient survival. PLoS One. 6:e175782011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Q, Murphy M, Ross J, Sheehan C and
Carlson JA: Skp2 and p27kip1 expression in melanocytic
nevi and melanoma: An inverse relationship. J Cutan Pathol.
31:633–642. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen G, Wang Y, Garate M, Zhou J and Li G:
The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated
ubiquitin-proteasome system. Oncogene. 29:1498–1508. 2010.
View Article : Google Scholar
|
|
33
|
Bhatia N, Herter JR, Slaga TJ, Fuchs SY
and Spiegelman VS: Mouse homologue of HOS (mHOS) is overexpressed
in skin tumors and implicated in constitutive activation of
NF-kappaB. Oncogene. 21:1501–1509. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nawrocki ST, Griffin P, Kelly KR and Carew
JS: MLN4924: A novel first-in-class inhibitor of NEDD8-activating
enzyme for cancer therapy. Expert Opin Investig Drugs.
21:1563–1573. 2012. View Article : Google Scholar : PubMed/NCBI
|
